Back
ESC Premium Access

The value of GRACE risk score for predicting mortality in heart failure patients admitted with Non ST elevation Acute Coronary Syndrome

Session: Chronic heart failure e-posters
Topic: Epidemiology, Prognosis, Outcome
Speaker: Doctor N. Bouzas Cruz (Santiago de Compostela, ES)
Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

0

About the speaker

Doctor Noelia Bouzas Cruz

University Hospital of Santiago de Compostela, Santiago de Compostela (Spain)
0 follower

218 more presentations in this session

Intermittent therapy with levosimendan in patients with advanced heart failure

Speaker: Professor M. Weis (Munich, DE)

Access
Abstract
Slides
0
Thumbnail

Differences in long-term all-cause and cardiovascular mortality according to heart failure aetiology in ambulatory patients

Speaker: Doctor G. Spitaleri (Badalona, ES)

Access
Abstract
Slides
0
Thumbnail

Comparing the central arterial stiffness indices in the decompensated and compensated states of heart failure: a cohort study

Speaker: Assistant Professor G. Youssef (Cairo, EG)

Access
Abstract
Slides
0
Thumbnail

Opportunities for clinician education in the pharmacotherapy of stable heart failure

Speaker: Doctor P. Murray (Dublin, IE)

Access
Abstract
Slides
0
Thumbnail

Systolic blood pressure visit-to-visit variability and clinical outcomes of heart failure with preserved ejection fraction

Speaker: Doctor Q. Zhang (Tianjin, CN)

Access
Abstract
Slides
0
Thumbnail

Access the full session

Chronic heart failure e-posters

Speakers: Doctor N. Bouzas Cruz, Professor M. Weis, Doctor G. Spitaleri, Assistant Professor G. Youssef, Doctor P. Murray...
Access
0
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress
logo Image

Related content

ESC Premium Access

SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

27 August 2021

ESC Premium Access

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

27 August 2021

ESC Premium Access

The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure

27 August 2021

ESC 365 is supported by

logo Novo Nordisk